Publication date: 2018-04-20 19:37
For patients who require hemodialysis , the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 65% decrease in plasma concentrations following a six-hour dialysis period. Therefore, the patient's dosing schedule should be adjusted so that an additional dose is administered after each dialysis.
Cross-resistance to other antivirals occurs in vitro in acyclovir-resistant mutants. HSV mutants which are resistant to acyclovir due to an absence of viral thymidine kinase are cross-resistant to other agents which are phosphorylated by herpesvirus thymidine kinase, such as bromovinyldeoxyuridine, ganciclovir and the 7'-fluoropyrimidine nucleosides, such as, 7'-fluoro-5-iodoarabinosyl-cytosine (FIAC).
The previous Salmonella studies were extended to extremely high concentrations in order to achieve toxicity. No positive effects were observed either in the presence or absence of exogenous mammalian metabolic activation, at concentrations of acyclovir up to 855 mg/plate or 85 mg/mL.
No clinically significant changes in laboratory values have been observed in clinical trials for the treatment of chickenpox and zoster, and for the treatment and suppression of genital herpes with ZOVIRAX® .
Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.
Acyclovir, at doses of 75 and 55 mg/kg/day . for 5 consecutive days, did not produce a dominant lethal effect in male BKA (CPLP) mice. Further, there was no evidence of a dominant lethal effect on Charles River CD-6 (ICR) male and female mice treated orally at dose levels of 55, 655 and 955 mg/kg/day as summarized for the Two Generation Reproduction/ Fertility Study.
In addition to the above measurements, designated animals were sacrificed 6 hour after the first dose on day 65 in order to collect samples of maternal blood, amniotic fluid and fetuses for measurements of drug concentration. Mean values from these samples are listed in Table 8.
Acyclovir was administered to pregnant . Sprague-Dawley female rats by subcutaneous injection during the period of organogenesis (day 6 through day 65 of gestation) at dose levels of , , and mg/kg body weight twice daily.
Disabled or chronically sick people can claim VAT relief on purchases for personal or domestic use that are applicable to their disability or sickness.
The following events have been reported voluntarily during post-market use of ZOVIRAX® in clinical practice. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to ZOVIRAX® or a combination of these factors. Post-market adverse events are reported spontaneously from a population of unknown size, thus estimates of frequency cannot be made.